Treating Opioid Use Disorder During Pregnancy
This NIDA policy brief shares evidence-based research on treating opioud use dissorder on pregnancy, including the assessment of methadone and buprenorphine as treatment.
This NIDA policy brief shares evidence-based research on treating opioud use dissorder on pregnancy, including the assessment of methadone and buprenorphine as treatment.
This provincial evidence-based guideline articulates the full range of therapeutic options for the optimal treatment of adults and youth with varying presentations of opioid use disorder. It is intended for use for all British Colombia (BC) physicians, nursing and allied health professionals, and other care providers involved in the treatment of individuals with opioid use disorder.
These guidelines contain recommendations on the identification and management of substance use and substance use disorders for health care services which assist women who are pregnant, or have recently had a child, and who use alcohol or drugs or who have a substance use disorder.
This brief describes the Screening, Brief Intervention, and Referral to Treatment (SBIRT) model for pregnant and postpartum women with substance use disorders and how to implement and integrate SBIRT into care delivery.
This report aims to address the treatment opportunities for pregnant and postpartum (or parenting) women (PPW) with substance use disorder (SUD) by describing opportunities to integrate obstetricians and gynecologists (OB/GYN) and SUD care as well as barriers to integrated care delivery.
HCUP Fast Stats provides easy access to the latest HCUP-based statistics for health care information topics. It uses visual statistical displays in stand-alone graphs, trend figures, or simple tables to convey complex information at a glance. Fast Stats is updated regularly for timely, topic-specific national and State-level statistics.
The LactMed® database contains information on drugs and other chemicals to which breastfeeding mothers may be exposed. It includes information on the levels of such substances in breast milk and infant blood, and the possible adverse effects in the nursing infant.
This FDA page provides an index of over 400 FDA approved drugs and their descriptions. Note that it does not include all FDA approved drugs, but shares other resources to find more information on drugs not included on the list.
SAMHSA offers evidence-based resources to help providers screen, diagnose, and deliver integrated care to patients with co-occurring disorders.
The following checklist intends to support health care teams in providing evidence-based recommendations for treating pregnant and postpartum patients with OUD. The checklist is divided into five sections, sequenced by timing of presentation to care.